[DOI] [PMC free article] [PubMed] [Google Scholar] 44.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., Wharton S., Yokote K., Zeuthen N., Kushner R.F., STEP 1 Study Group Once-weekly semaglutide in adults with overweight or obesity
HAEC were incubated in EGM2 until enough amount could be secured for experiment
Second, significant heterogeneity in therapeutic responses to GLP-1RAs across individuals has been observed
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favourable benefit-safety profile
This challenges the idea that anti-inflammatory benefits are solely a result of weight loss